Ultragenyx Pharma (RARE) Misses Q1 EPS by 79c, Revenues Beat

Ultragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($2.03), $0.79 worse than the analyst estimate of ($1.24). Revenue for the quarter came in at $99.4 million versus the consensus estimate of $77.04 million.

“We continue to have strong Crysvita and Dojolvi launches and execute on our development priorities across our pipeline,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. “In 2021, we will have ongoing pivotal trials for three gene therapies, one pivotal monoclonal antibody study for osteogenesis imperfecta, our first mRNA program for GSDIII, and an antisense oligonucleotide for Angelman with our partner GeneTx. These six clinical programs along with our commercial and early-stage programs make ours one of the most diversified pipelines in rare disease.”

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Visa (V) stock rises as Q2 earnings, revenue come ahead of estimates
• Retail Opportunity Investments (ROIC) Tops Q1 EPS by 2c, reaffirms guidance
• KKR Real Estate Finance Trust (KREF) Tops Q1 EPS by 4c